We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Common Drug Found to Prevent Adhesions

By HospiMedica staff writers
Posted on 08 Feb 2005
In an accidental discovery, researchers have found that short-term use of the COX-2 inhibitor Celebrex, a drug for arthritis whose use is now under investigation, can prevent adhesions following surgery. More...
The finding was reported in the January 25, 2000, issue of Annals of Surgery.

Adhesions develop in 55-90% of patients undergoing surgery, causing pain and complications. Adhesions are a major cause of bowel obstruction and infertility, so repeat surgery is often required to cut through them. No good way to prevent them has been found. Now, researchers studying the effects of Celebrex on liver rejuvenation after injury happened to notice there were no adhesions, so they decided to conduct a formal experiment. After undergoing surgery, groups of six to 18 mice received either Celebrex or another COX-2 inhibitor, Vioxx, nonselective COX inhibitors (such as ibuprofen and aspirin), or placebo for 10 days.

At the end of 10 days, the placebo group had obvious abdominal adhesions. Mice receiving COX inhibitors had a slight reduction in adhesions, those receiving nonselective COX inhibitors had a larger reduction, and 55% (six of 11) of those given Celebrex were completely adhesion-free. After observing the group for another 25 days, the adhesion score (based on the extent and removal difficulty) was only 1 in the Celebrex group, 5 in the Vioxx group, 8 in the aspirin group, and 11 in the placebo group.

Currently, the most common method of preventing adhesions uses a barrier agent or gel to separate the abdominal surfaces and prevent them from binding together. However, these treatments can suppress the immune system, cause infection, and impair healing.

"If Celebrex works in humans, you could give it to patients on the day of abdominal surgery and the 10 days after surgery,” noted senior investigator Dr. Mark Puder, of the department of surgery and the vascular biology program at Children's Hospital Boston (MA, USA). Dr. Puder believes that COX-2 inhibitors could also reduce adhesions after gynecologic and thoracic surgery.




Related Links:
Children's Hospital Boston

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Pocket Fetal Doppler
CONTEC10C/CL
New
Captivator EMR Device
Captivator Endoscopic Mucosal Resection Device
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.